Prevalence, screening and treatment of latent tuberculosis among oral corticosteroid recipients

To the Editor:

Tuberculosis guidelines identify individuals receiving the corticosteroid drug prednisone (or its equivalent) at a dose of \(>15\) mg·day\(^{-1}\) for 2–4 weeks or more as a group at risk of tuberculosis if infected with \(Mycobacterium\) \(tuberculosis\) \([1, 2]\). There is an eight-fold increased risk of developing active tuberculosis with such drugs at this dose \([3]\). However, there is no information on the epidemiology of latent tuberculosis infection (LTBI), screening and treatment among oral corticosteroid users. Tuberculosis guidelines recommend using a threshold of \(\geq 5\) mm induration to identify latent infection among oral corticosteroid recipients \([1, 2]\) but this recommendation is not evidence-based. The purpose of this study was to describe the prevalence, screening and treatment of LTBI among oral corticosteroid recipients in the USA.

This was a cross-sectional study using US nationally representative, population-level data from the 1999–2000 National Health and Nutrition Examination Survey (NHANES). A description of the survey design and methodology appears elsewhere \([4]\). Self-reported medication receipt within the past month that required a prescription was collected by NHANES. Medication receipt was confirmed in \(83.3\%\) of participants through examiner inspection of prescription containers \([5]\). Survey participants who received any corticosteroid in an oral formulation within the past month were considered "recipients". Survey participants who did not receive any oral corticosteroids within the past month were considered "nonrecipients". Topical, inhaled or intra-articular corticosteroids were not included in this study.

Information on total duration of corticosteroid receipt was collected but not dose. A single-step tuberculin skin test (TST) was implanted and available in 7317 participants (no age restriction), excluding individuals with a self-reported history of previous severe reaction to TST, active severe skin conditions over the arms, and a known or uncertain history of self-reported, doctor-diagnosed, active tuberculosis. NHANES also collected information on self-reported history of previous TST and receipt of antibiotic therapy for LTBI among individuals with a previously positive TST. The distribution of size of TST induration, and the prevalence of LTBI, previous TST screening and previous receipt of chemoprophylaxis for LTBI were described among corticosteroid recipients and nonrecipients.

Of the 7317 participants, 93 (1.3%) were oral corticosteroid recipients and 7224 (98.7%) were nonrecipients. The average duration of corticosteroid receipt was 1002 days, with 73% of recipients taking a corticosteroid for \(\geq 2\) weeks. Significantly greater proportions of corticosteroid recipients versus nonrecipients were older in age, had a bacille Calmette–Guerin (BCG) vaccination scar, were obese, or had asthma, COPD or arthritis (data not shown). The distribution of the size of TST induration among corticosteroid recipients was leftward-shifted relative to nonrecipients, such that 87.5% of recipients had a TST induration of \(0\) mm versus \(80.5\%\) of nonrecipients (fig. 1). Compared with nonrecipients, there were nonsignificant trends towards fewer recipients demonstrating a positive TST, as defined by an induration \(\geq 5\) mm (3.1% versus 6.1%, \(p=0.22\)). Assuming corticosteroid recipients have, at minimum, the same prevalence of LTBI as nonrecipients (i.e. 4.1% based on a TST cut-off of \(\geq 10\) mm), a TST cut-off of \(\sim 3.5\) mm induration would be needed among recipients to denote positivity in order to obtain the same prevalence of LTBI. Compared with nonrecipients, a nonsignificant trend towards fewer recipients having undergone previous TST screening was found (62.9% versus 71.6%, \(p=0.07\)). Compared with nonrecipients, no corticosteroid recipients had received antibiotic prophylaxis (0% versus 44.3%, \(p=0.54\)).

The lower prevalence of LTBI among corticosteroid recipients versus nonrecipients is probably not real and, instead, a reflection of the drugs’ known ability to suppress TST reactivity \([6–9]\). Given the evidence for TST suppression by systemic corticosteroids, TB guidelines recommend using a lower-than-usual TST threshold of \(\geq 5\) mm induration to denote positivity among corticosteroid recipients \([1, 2]\) but this cut-off is not evidence-based. Our data demonstrate a TST cut-off of \(\sim 3.5\) mm induration would be needed among corticosteroid recipients to obtain the same prevalence of LTBI as in the general population. The findings of trends towards less TST screening and less chemoprophylaxis for positive TST cases among corticosteroid recipients are concerning, as these factors may be contributing to the development of active tuberculosis in this already tuberculosis-vulnerable population. Our finding of higher frequency of previous BCG...
vaccination in the corticosteroid group may, in part, explain the trends towards less screening and chemoprophylaxis in this group.

There are several limitations to the present study. First, it was based on data from 1999 to 2000 and more recent data were not available for analysis. Second, the small sample size of corticosteroid recipients may have impeded our ability to detect statistically significant differences with respect to TST screening and chemoprophylaxis receipt between the two groups. Increasing sample size numbers was not possible by us, as data collection was undertaken by the US Centers for Disease Control. Third, our purpose was not to determine if corticosteroid receipt was independently associated with LTBI diagnosis, screening and treatment, but instead to perform descriptive analysis, as oral corticosteroid receipt is already recognised by tuberculosis guidelines as a circumstance for targeted screening and treatment. The small sample size of corticosteroid recipients also precluded us from examining possible independent associations. Fourth, some individuals with a positive TST whom we considered to have LTBI may have been false positives due to

<table>
<thead>
<tr>
<th>Participants n (%)</th>
<th>Corticosteroid# recipients</th>
<th>Corticosteroid# nonrecipients</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence of LTBI by NHANES TST</td>
<td>93 (1.3)</td>
<td>7224 (98.7)</td>
<td></td>
</tr>
<tr>
<td>&gt;10 mm induration cut-off</td>
<td>1/93 (1.5)</td>
<td>293/7224 (4.1)</td>
<td>0.21</td>
</tr>
<tr>
<td>&gt;5 mm induration cut-off</td>
<td>3/93 (3.1)</td>
<td>443/7224 (6.1)</td>
<td>0.22</td>
</tr>
<tr>
<td>Prevalence of previous TST screening</td>
<td>59/93 (62.9)</td>
<td>4936/6897 (71.6)</td>
<td>0.07</td>
</tr>
<tr>
<td>Prevalence of chemoprophylaxis receipt for LTBI among individuals with a previously reported positive TST</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Individuals with &gt;10 mm induration on NHANES TST</td>
<td>0/0</td>
<td>42/94 (44.7)</td>
<td>0.53</td>
</tr>
<tr>
<td>Individuals with &gt;5 mm induration on NHANES TST</td>
<td>0/0</td>
<td>52/118 (44.3)</td>
<td>0.54</td>
</tr>
</tbody>
</table>

FIGURE 1 a) Distribution of tuberculin skin test (TST) induration, and b) prevalence of latent tuberculosis infection (LTBI), screening and preventative therapy among corticosteroid recipients and nonrecipients. Data are presented as n/N (%) unless otherwise stated. NHANES: National Health and Nutrition Examination Survey. #: cortisone acetate, dexamethasone, fludrocortisone acetate, hydrocortisone, methylprednisolone, prednisolone, prednisolone sodium phosphate or prednisone; +: n=294 (4.0%); #: n=446 (6.1%).

There are several limitations to the present study. First, it was based on data from 1999 to 2000 and more recent data were not available for analysis. Second, the small sample size of corticosteroid recipients may have impeded our ability to detect statistically significant differences with respect to TST screening and chemoprophylaxis receipt between the two groups. Increasing sample size numbers was not possible by us, as data collection was undertaken by the US Centers for Disease Control. Third, our purpose was not to determine if corticosteroid receipt was independently associated with LTBI diagnosis, screening and treatment, but instead to perform descriptive analysis, as oral corticosteroid receipt is already recognised by tuberculosis guidelines as a circumstance for targeted screening and treatment. The small sample size of corticosteroid recipients also precluded us from examining possible independent associations. Fourth, some individuals with a positive TST whom we considered to have LTBI may have been false positives due to
In conclusion, the current guideline-recommended TST threshold of $\geq 5$ mm to denote positivity among recipients of oral corticosteroids may need to be lowered to $\sim 3.5$ mm in order to adequately capture LTBI in this at-risk group but further research with prospective data and adjustment for confounders is required. Fewer oral corticosteroid recipients were screened and treated for LTBI compared with nonrecipients, which may be placing this group at heightened risk. More frequent screening for LTBI and chemoprophylaxis of infected cases are probably needed among tuberculosis-vulnerable oral corticosteroid recipients.

**References**